To Get Help Now
Personal Injury Lawsuits
Click Here
 
Today's Date:

Hysterectomy Procedure may Spread Cancer

A new study has provided more evidence that a hysterectomy procedure known as power morcellation may spread cancer.

The procedure, performed on about 50,000 women a year, uses a device to cut uterine tissue into pieces before removing them through small incisions made during minimally invasive surgery, the New York Times reported. The procedure is also used to remove fibroid tumors. More Hysterectomy Procedure may Spread Cancer

Non-Profit Group Pushes FDA to Reveal Prior Pre-Clinical Animal Testing to Clinical Trial Participants

A non-profit organization is fighting to make sure that those who participate in clinical drug trials are informed when the drugs have been tested previously on animals.

The Center for Responsible Science is pushing for the U.S. Food and Drug Administration (FDA) to upgrade its regulations to reveal animal testing in the clinical trial documentation given to participants. The group says the documentation rarely mentions animal testing and whether or not that information can help predict whether a drug is safe for use in humans, according to The Wall Street Journal’s Pharmalot blog. More Non-Profit Group Pushes FDA to Reveal Prior Pre-Clinical Animal Testing to Clinical Trial Participants

Human Sues Medtronic, Accuses the Company of Falsely Representing its Infuse Bone Growth Product

Managed care company Humana has sued Medtronic Inc., accusing the company of falsely representing its Infuse bone growth device as safe and effective in spinal fusion surgeries.

Humana filed the lawsuit in federal court in Tennessee on Friday. The complaint alleges that Medtronic paid for academic literature that fraudulently portrayed Infuse as safe and effective for off-label uses. According to court documents, Humana said that Medtronic engaged in a “sophisticated and deeply deceptive marketing strategy” designed to expand the market for Infuse, by urging and compensating spine surgeons to use the device by over-emphasizing its benefits and downplaying its serious risks, Reuters reported. More Human Sues Medtronic, Accuses the Company of Falsely Representing its Infuse Bone Growth Product

Study Links Excessive Cell Phone Use to Brain Tumors

People who use their cell phones with great frequency may be at an elevated risk of being diagnosed with a brain tumor, according to a new French study.

The study authors cautioned that it’s still not clear if there’s added risk for the majority of cell phone users, but say a link may exist between excessive cell phone use and brain tumors. They added, that since the devices and the way people use them is ever-changing, more research is needed going forward, Fox News reported. More Study Links Excessive Cell Phone Use to Brain Tumors

Medtronic Tries to Settle Infuse Cases but Many Patients May Still See Their Day in Court

More than 6,500 reports of injuries related to Medtronic’s Infuse bone growth product have flooded into the U.S. Food and Drug Administration (FDA) since 2002. About 3,300 were registered with the agency’s medical device reporting system last year alone. Now, the company is settling as many cases as possible while patients await their day in court.

Medtronic told investors last week that it will pay $22 million to settle about 950 claims and is setting aside $140 million to settle future claims, according to MedPageToday.com. More Medtronic Tries to Settle Infuse Cases but Many Patients May Still See Their Day in Court

Chicago Jury Decides Takeda Pharmaceutical Co. is not Responsible for Man’s Bladder Cancer Death

Takeda Pharmaceutical Co. is not responsible for the death of a man who died in 2006 after taking the Type 2 diabetes drug Actos, a jury decided yesterday.

A lawyer for the family of William Whitlach, 57, urged the jury to award at least $10 million to his wife and children for pain, suffering, and financial losses caused by his death. During the closing arguments of the four-week trial, the attorney said Takeda continued to sell its Actos even though it knew caused bladder cancer in order to maximize returns before competing generic versions reached the market, BusinessWeek.com reported. More Chicago Jury Decides Takeda Pharmaceutical Co. is not Responsible for Man’s Bladder Cancer Death

HHS Probes Cardiac Defibrillators Manufactured by Boston Scientific Corp.

This week, the U.S. Department of Health and Human Services (HHS) subpoenaed Boston Scientific Corporation for information relating to the medical device maker’s 2008 launch of two brands of implantable cardiac defibrillators (ICDs) and their performance between 2007 and 2009, as well as the operation of a “Physical Guided Learning Program.”

The defibrillators are sold under the brand names Cognis and Teligen, according to the Wall Street Journal (WSJ). More HHS Probes Cardiac Defibrillators Manufactured by Boston Scientific Corp.

Morcellators Used in Fibroid Surgeries Could Spread Unseen Cancer, Johnson & Johnson Warns

Johnson & Johnson (J&J) has suspended the sale of morcellators, which are devices used in fibroid surgeries, over concerns that they can spread a type of rare but deadly cancer.

The medical device maker is stopping the world-wide sale, distribution, and promotion of laparoscopic power morcellators, but is not permanently pulling them from the market, according to Reuters. More Morcellators Used in Fibroid Surgeries Could Spread Unseen Cancer, Johnson & Johnson Warns

Remington Model 700 and Remington Model Seven Rifles Recalled Due to Risk of Unintentional Discharge

Gun manufacturer Remington has announced a safety recall of Model 700 and Model Seven rifles. The rifles affected by the recall have a X-Mark Pro, or XMP triggers and were manufactured between May 1, 2006 and April 9, 2014.

The recall was issued after Remington found out that rifles equipped with the XMP trigger can fire unintentionally, according to Gunds.com. The issue is very dangerous and could prove fatal if not addressed. Remington said the issue is specific to the XMP trigger only, and all other Model 700 and Model Seven rifles are unaffected by the recall. More Remington Model 700 and Remington Model Seven Rifles Recalled Due to Risk of Unintentional Discharge

EU Regulators Reviewing Testosterone Medication Heart Risks

The European Medicines Agency is reviewing testosterone medications after studies suggested the drugs may be linked to cardiovascular risks.

The European Union’s (EU) drug regulator will study the benefits and risks of testosterone products and conclude whether the marketing for the medications should be maintained, altered, suspended, or withdrawn, Bloomberg.com reported. More EU Regulators Reviewing Testosterone Medication Heart Risks